Decision to implant a cardioverter defibrillator after myocardial infarction: The role of ejection fraction v. other risk factor markers

Keyphrases

• Aggregate Value 50%
• Ancillary 50%
• Arrhythmia 50%
• Arrhythmia Suppression 50%
• Arrhythmogenic Substrate 100%
• Autonomic Tone 50%
• Block Therapy 100%
• Cardioverter-defibrillator 100%
• Cardioverter-defibrillator Implantation 50%
• Clinical Test 50%
• Clinical Testing 50%
• Conventional Therapy 50%
• Ejection Fraction 100%
• Electrophysiologic 50%
• Heart Rate Variability 100%
• High Risk 100%
• Implantable Defibrillator 50%
• Left Ventricular Ejection Fraction 50%
• Low Ejection Fraction 100%
• Low Risk 100%
• Myocardial Infarction 100%
• Myocardial Infarction Patients 50%
• Non-invasive Biomarkers 50%
• Nonsustained Ventricular Tachycardia 50%
• Operational Value 50%
• Post-myocardial Infarction 50%
• Premature Ventricular Contraction 50%
• Primary Prevention 50%
• Prior Probability 50%
• Project Risk 50%
• Receiver Operating Characteristic 50%
• Receiver Operating Characteristic Curve 50%
• Registry Data 50%
• Relative Reduction 50%
• Risk Estimation 50%
• Risk Factors 100%
• Risk of Death 50%
• Risk Stratification 50%
• Similarity Data 50%
• Therapy Groups 50%
• Trial Registries 50%
• Ventricular Arrhythmia 50%

Medicine and Dentistry

• Arrhythmia 25%
• Beta Adrenergic Receptor Blocking 50%
• Cardiac Dysrhythmia 75%
• Defibrillator 100%
• Ejection Fraction 100%
• Group Therapy 25%
• Heart Left Ventricle Ejection Fraction 25%
• Heart Rate Variability 50%
• Implantable Automatic Defibrillator 25%
• Multicenter Automatic Defibrillator Implantation Trial 25%
• Myocardial Infarction 100%
• Nonsustained Ventricular Tachycardia 25%
• Prematurity 25%
• Primary Prevention 25%
• Risk Evaluation 25%
• Risk Stratification 25%
• Sensitivity and Specificity 50%